Cargando…
Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a te...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602093/ https://www.ncbi.nlm.nih.gov/pubmed/33066188 http://dx.doi.org/10.3390/jcm9103281 |
_version_ | 1783603590073417728 |
---|---|
author | Keller, Karsten Göbel, Sebastian ten Cate, Vincent Panova-Noeva, Marina Eggebrecht, Lisa Nagler, Markus Coldewey, Meike Foebel, Maike Bickel, Christoph Lauterbach, Michael Espinola-Klein, Christine Lackner, Karl J. ten Cate, Hugo Münzel, Thomas S. Wild, Philipp H. Prochaska, Jürgen |
author_facet | Keller, Karsten Göbel, Sebastian ten Cate, Vincent Panova-Noeva, Marina Eggebrecht, Lisa Nagler, Markus Coldewey, Meike Foebel, Maike Bickel, Christoph Lauterbach, Michael Espinola-Klein, Christine Lackner, Karl J. ten Cate, Hugo Münzel, Thomas S. Wild, Philipp H. Prochaska, Jürgen |
author_sort | Keller, Karsten |
collection | PubMed |
description | Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011–March 2013). Patients were evaluated using clinical visits, computer-assisted personal interviews, self-reported data and laboratory measurements according to standard operating procedures. Overall, 360 patients with VTE from RMC and 254 from CS were included. Time in therapeutic range (TTR) was higher in CS compared to RMC (76.9% (interquartile range [IQR] 63.2–87.1%) vs. 69.5% (52.3–85.6%), p < 0.001). Crude rate of thromboembolic events (rate ratio [RR] 11.33 (95% confidence interval [CI] 1.85–465.26), p = 0.0015), clinically relevant bleeding (RR 6.80 (2.52–25.76), p < 0.001), hospitalizations (RR 2.54 (1.94–3.39), p < 0.001) and mortality under OAC (RR 5.89 (2.40–18.75), p < 0.001) were consistently higher in RMC compared with CS. Patients in RMC had higher risk for primary outcome (clinically relevant bleedings, thromboembolic events and mortality, hazard ratio [HR] 5.39 (95%CI 2.81–10.33), p < 0.0001), mortality (HR 5.54 (2.22–13.84), p = 0.00025), thromboembolic events (HR 6.41 (1.51–27.24), p = 0.012), clinically relevant bleeding (HR 5.31 (1.89–14.89), p = 0.0015) and hospitalization (HR 1.84 (1.34–2.55), p = 0.0002). Benefits of CS care were still observed after adjusting for comorbidities and TTR. In conclusion, anticoagulation quality and outcome of VTE patients undergoing VKA treatment was significantly better in CS than in RMC. Patients treated in CS had lower rates of adverse events, hospitalizations and lower mortality. CS was prognostically relevant, beyond providing advantages of improved international ratio (INR) monitoring. |
format | Online Article Text |
id | pubmed-7602093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76020932020-11-01 Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study Keller, Karsten Göbel, Sebastian ten Cate, Vincent Panova-Noeva, Marina Eggebrecht, Lisa Nagler, Markus Coldewey, Meike Foebel, Maike Bickel, Christoph Lauterbach, Michael Espinola-Klein, Christine Lackner, Karl J. ten Cate, Hugo Münzel, Thomas S. Wild, Philipp H. Prochaska, Jürgen J Clin Med Article Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011–March 2013). Patients were evaluated using clinical visits, computer-assisted personal interviews, self-reported data and laboratory measurements according to standard operating procedures. Overall, 360 patients with VTE from RMC and 254 from CS were included. Time in therapeutic range (TTR) was higher in CS compared to RMC (76.9% (interquartile range [IQR] 63.2–87.1%) vs. 69.5% (52.3–85.6%), p < 0.001). Crude rate of thromboembolic events (rate ratio [RR] 11.33 (95% confidence interval [CI] 1.85–465.26), p = 0.0015), clinically relevant bleeding (RR 6.80 (2.52–25.76), p < 0.001), hospitalizations (RR 2.54 (1.94–3.39), p < 0.001) and mortality under OAC (RR 5.89 (2.40–18.75), p < 0.001) were consistently higher in RMC compared with CS. Patients in RMC had higher risk for primary outcome (clinically relevant bleedings, thromboembolic events and mortality, hazard ratio [HR] 5.39 (95%CI 2.81–10.33), p < 0.0001), mortality (HR 5.54 (2.22–13.84), p = 0.00025), thromboembolic events (HR 6.41 (1.51–27.24), p = 0.012), clinically relevant bleeding (HR 5.31 (1.89–14.89), p = 0.0015) and hospitalization (HR 1.84 (1.34–2.55), p = 0.0002). Benefits of CS care were still observed after adjusting for comorbidities and TTR. In conclusion, anticoagulation quality and outcome of VTE patients undergoing VKA treatment was significantly better in CS than in RMC. Patients treated in CS had lower rates of adverse events, hospitalizations and lower mortality. CS was prognostically relevant, beyond providing advantages of improved international ratio (INR) monitoring. MDPI 2020-10-13 /pmc/articles/PMC7602093/ /pubmed/33066188 http://dx.doi.org/10.3390/jcm9103281 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Keller, Karsten Göbel, Sebastian ten Cate, Vincent Panova-Noeva, Marina Eggebrecht, Lisa Nagler, Markus Coldewey, Meike Foebel, Maike Bickel, Christoph Lauterbach, Michael Espinola-Klein, Christine Lackner, Karl J. ten Cate, Hugo Münzel, Thomas S. Wild, Philipp H. Prochaska, Jürgen Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study |
title | Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study |
title_full | Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study |
title_fullStr | Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study |
title_full_unstemmed | Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study |
title_short | Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study |
title_sort | telemedicine-based specialized care improves the outcome of anticoagulated individuals with venous thromboembolism—results from the thrombeval study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602093/ https://www.ncbi.nlm.nih.gov/pubmed/33066188 http://dx.doi.org/10.3390/jcm9103281 |
work_keys_str_mv | AT kellerkarsten telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT gobelsebastian telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT tencatevincent telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT panovanoevamarina telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT eggebrechtlisa telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT naglermarkus telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT coldeweymeike telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT foebelmaike telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT bickelchristoph telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT lauterbachmichael telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT espinolakleinchristine telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT lacknerkarlj telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT tencatehugo telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT munzelthomas telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT swildphilipp telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy AT hprochaskajurgen telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy |